Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung

• Published in: Bioscience reports Vol. 41; no. 1
• Main Authors: Miao, Huikai, Chen, Dongni, Li, Rongzhen, Hu, Jia, Chen, Youfang, Xu, Chunmei, Wen, Zhesheng
• Format: Journal Article
• Language: English
• Published: England Portland Press Ltd The Biochemical Society 29.01.2021; Portland Press Ltd
• Subjects: Adenocarcinoma; Adenocarcinoma of Lung - genetics; Adenocarcinoma of Lung - immunology; Adenocarcinoma of Lung - metabolism; Adult; Aged; Aged, 80 and over; Algorithms; B-Lymphocytes - immunology; Bioinformatics; Biomarkers; Biomarkers, Tumor - metabolism; Cancer; Candidates; Cohort Studies; Computational Biology - methods; Datasets as Topic; Female; Gene expression; Genomes; Heterogeneity; Humans; Immune system; Immunotherapy; Infiltration; Information retrieval; Lung cancer; Lung Neoplasms - genetics; Lung Neoplasms - immunology; Lung Neoplasms - metabolism; Lungs; Lymphocytes B; Lymphocytes, Tumor-Infiltrating - immunology; Male; Medical prognosis; Metastases; Metastasis; Middle Aged; Molecular modelling; Non-coding RNA; Patients; Principal components analysis; Prognosis; Proteolysis; Risk groups; Risk levels; RNA; RNA, Long Noncoding - genetics; RNA, Long Noncoding - immunology; Signal Transduction; Software; Survival; Survival analysis; Transcriptomes; Tumorigenesis; Ubiquitin; Ubiquitin - metabolism; long noncoding RNA; prognosis signature; immune; adenocarcinoma of lung

Background: Lung adenocarcinoma (LUAD) is a heterogeneous disease with high mortality. Close attention has been paid to immunotherapy in LUAD treatment. However, immunotherapy has produced different therapeutic effects because of immune heterogeneity. Long noncoding RNAs (lncRNAs) are survival progn...